89bioETNB
ETNB
About: 89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
Employees: 93
0
Funds holding %
of 7,407 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
109% more repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 35
100% more funds holding in top 10
Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]
68% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 19
23% more capital invested
Capital invested by funds: $774M [Q3] → $949M (+$175M) [Q4]
8% more funds holding
Funds holding: 144 [Q3] → 155 (+11) [Q4]
4.47% more ownership
Funds ownership: 98.66% [Q3] → 103.14% (+4.47%) [Q4]
84% less call options, than puts
Call options by funds: $1.38M | Put options by funds: $8.89M
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$11
82%
upside
Avg. target
$24
292%
upside
High target
$38
527%
upside
4 analyst ratings
3 positive
75%
1 neutral
25%
0 negative
0%
Goldman Sachs | 82%upside $11 | Neutral Initiated | 14 Mar 2025 |
Citigroup Geoff Meacham 36% 1-year accuracy 12 / 33 met price target | 313%upside $25 | Buy Initiated | 13 Mar 2025 |
HC Wainwright & Co. Ed Arce 33% 1-year accuracy 50 / 152 met price target | 247%upside $21 | Buy Reiterated | 28 Feb 2025 |
UBS Eliana Merle 16% 1-year accuracy 3 / 19 met price target | 527%upside $38 | Buy Maintained | 31 Jan 2025 |
Financial journalist opinion
Positive
Seeking Alpha
1 day ago
89bio: A Buy With Strong Market Opportunity In MASH And SHTG
Initiate Buy rating for 89bio, Inc. due to promising lead candidate pegozafermin targeting MASH and SHTG with encouraging Phase 2 data. Pegozafermin may have faster fibrosis improvement and better safety profile compared to competitors, potentially capturing significant market share in MASH and SHTG. Financially, 89bio has a solid cash position but may need to raise capital by mid to late 2026, posing dilution risk.
Positive
Zacks Investment Research
1 month ago
Bears are Losing Control Over 89BIO (ETNB), Here's Why It's a 'Buy' Now
89BIO (ETNB) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Positive
Zacks Investment Research
1 month ago
Is 89BIO (ETNB) Stock Outpacing Its Medical Peers This Year?
Here is how 89BIO (ETNB) and Eton Pharmaceuticals, Inc. (ETON) have performed compared to their sector so far this year.
Neutral
GlobeNewsWire
1 month ago
89bio to Participate in the Leerink Partners Global Healthcare Conference
SAN FRANCISCO, March 03, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Company's Management will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Monday, March 10, 2025 at 4:20 PM EST and participate in one-on-one investor meetings. The webcast of the fireside chat will be accessible in the investor section of 89bio's website.
Neutral
GlobeNewsWire
1 month ago
89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates
– ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic dysfunction-associated steatohepatitis (MASH) continue to advance with topline histology data expected in 1H 2027 and 2028, respectively – –The Phase 3 ENTRUST trial in severe hypertriglyceridemia (SHTG) will be unblinded after study completion at Week 52 vs. Week 26 following discussions with the U.S. Food and Drug Administration (FDA); topline data are now expected in 1Q 2026 – – Cash, cash equivalents, and marketable securities totaled $440.0 million as of December 31, 2024; a follow-on offering in the 1Q 2025 resulted in gross proceeds of $287.5 million – SAN FRANCISCO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today reported its financial results for the fourth quarter and full year ended December 31, 2024, and provided corporate updates.
Positive
Zacks Investment Research
1 month ago
Should You Buy 89BIO (ETNB) After Golden Cross?
89BIO (ETNB) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, ETNB's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts See a 171.42% Upside in 89BIO (ETNB): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 171.4% in 89BIO (ETNB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Positive
24/7 Wall Street
2 months ago
Insider Buying Surges in February, Especially in These 6 Stocks
In January, the number of notable insider purchases was somewhat muted.
Neutral
GlobeNewsWire
2 months ago
89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN FRANCISCO, Feb. 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 163,650 shares of the Company's common stock to seven new employees (the “Inducement Grants”) on January 31, 2025 (the “Grant Date”). The Inducement Grants have been granted pursuant to the Company's 2023 Inducement Plan (the “Plan”). The Inducement Grants were granted as an inducement material to these individuals entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4).
Positive
Zacks Investment Research
2 months ago
Wall Street Analysts Think 89BIO (ETNB) Could Surge 219.06%: Read This Before Placing a Bet
The average of price targets set by Wall Street analysts indicates a potential upside of 219.1% in 89BIO (ETNB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Charts implemented using Lightweight Charts™